logo-loader
viewApricus Biosciences Inc

Apricus Biosciences raises US$4.6mln through share issue

San Diego-based, Apricus’s key product is erectile disfunction cream Vitaros

picture of dollars
Money will fund roll-out of Vitaros across Europe

Apricus Biosciences, Inc (NASDAQ:APRI) has raised US$4.6mln through a placing with institutional shareholders at US$0.35.

The issue comes with a warrant  exercisable at US$0.45 per share with the money earmarked for general working capital.

San Diego-based, Apricus’s key product is erectile disfunction cream Vitaros, which is being steadily rolled out in Europe.

Earlier this month, Slovakia and the Czech Republic became the two latest European countries where the product went on sale.

The group intends to re-file its application for the US later this year after the Food and Drug Administration raised safety and manufacturing in the original Vitaros submission.

Shares eased 14% to 0.342.

 

Quick facts: Apricus Biosciences Inc

Price: - -

NASDAQ:APRI
Market: NASDAQ
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Opyl is new name of digital health track company ShareRoot

Opyl Limited (ASX:OPL) chief executive officer Michelle Gallaher updates Proactive on the renaming of the global digital health track company formerly known as ShareRoot Ltd (ASX:SRO). This heralds the company’s entry into the rapidly expanding global digital health and artificial...

33 minutes ago

2 min read